Welcome to our dedicated page for Essa Pharma news (Ticker: EPIX), a resource for investors and traders seeking the latest updates and insights on Essa Pharma stock.
This page provides an archive of news coverage for ESSA Pharma Inc. (former NASDAQ: EPIX), a pharmaceutical company that was previously focused on developing novel and proprietary therapies for patients with prostate cancer. The news items collected here document ESSA’s transition from a clinical-stage oncology-focused issuer to a company that discontinued and wound up its business in connection with an acquisition by XenoTherapeutics Inc.
According to ESSA’s press releases, the company entered into a Business Combination Agreement with XenoTherapeutics, a Massachusetts-based non-profit biotechnology organization, under which a wholly owned Xeno subsidiary acquired all of the issued and outstanding ESSA common shares. The news flow tracks key milestones in this process, including the announcement of the definitive agreement, applications to the Supreme Court of British Columbia for interim and distribution orders, and the scheduling and adjournment of special meetings of shareholders, optionholders and warrantholders.
Readers can review announcements related to ESSA’s US$80 million return of capital distribution, Nasdaq’s due bill trading mechanics for that distribution, subsequent clarifications about the due bill period, and updates on revised financial terms of the transaction. Later releases describe securityholder approval of the arrangement, court approval, and the closing of the acquisition, as well as ESSA’s request for delisting from Nasdaq.
For investors and researchers, this news archive offers detailed historical context on how ESSA managed its corporate transaction, cash distributions, and governance approvals leading up to its acquisition and delisting. It is useful for understanding the sequence of events that affected holders of EPIX shares and for examining how a publicly traded pharmaceutical issuer executed a court-supervised plan of arrangement and winding-up process.
ESSA Pharma Inc. (NASDAQ: EPIX), a clinical-stage pharmaceutical company, announced its participation at the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 25, 2023, at 2:00 p.m. Eastern Time in Toronto, Ontario. Key executives, including President and CEO David R. Parkinson, COO Peter Virsik, and CFO David S. Wood, will engage in one-on-one meetings with investors.
The conference connects U.S. and Canadian investors with updates on the Canadian healthcare sector and features both presentations and private meetings with prominent companies. A live webcast of ESSA's presentation will be available on the company’s website, with an archived version accessible for 90 days thereafter.
FAQ
What is the current stock price of Essa Pharma (EPIX)?
What is the market cap of Essa Pharma (EPIX)?
